Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said it was accepted into the Nvidia (NVDA) Connect program.
Intraday trading volume catapulted to over 155 million shares from a daily average of about 2.48 million.
Lipella Pharmaceuticals (LIPO) said its treatment candidate for oral lichen planus showed "clinically meaningful" reductions in pain, ulceration, and inflammation across all key metrics in a phase 2a trial.
Shares soared about 36% as intraday trading volume surged to over 37.2 million from a daily average of about 1.59 million.
Travere Therapeutics (TVTX) said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari for focal segmental glomerulosclerosis, a rare kidney disorder.
Wedbush raised its price target on the stock to $30 from $26 while maintaining its outperform rating.
Shares of Travere rose 13% as intraday trading volume climbed to over 3.62 million from a daily average of about 1.29 million.
Price: 8.01, Change: +4.91, Percent Change: +158.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.